Interaction between methotrexate and ciprofloxacin.
(2002)
Journal - Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology (United States )
Abstract :
High-dose methotrexate is used in malignant hemopathies and solid tumors in children. Methotrexate serum concentrations must be monitored because of the possible toxicity of drug elimination delay. Several drugs (e.g., penicillin, probenecid) can alter the elimination of methotrexate. The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.
| ISSN : | 1077-4114 |
|---|
| Mesh Heading : | Adolescent Anti-Infective Agents Antimetabolites, Antineoplastic Bone Neoplasms Child Child, Preschool Ciprofloxacin Drug Interactions Female Humans Male Methotrexate Neuroblastoma Osteosarcoma pharmacokinetics drug therapy pharmacokinetics blood pharmacokinetics drug therapy drug therapy |
|---|
| Mesh Heading Relevant : | adverse effects adverse effects adverse effects adverse effects |
|---|
[Cutaneous symptoms revealing a monoblastic leukemia]
(2002)
Journal - Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie (France )
Abstract :
Leukemia cutis (LC) are not rare in acute myeloid leukaemia (AML) in children but exceptionally reveal it. Most authors think that they have poor prognosis. CASE REPORT: We report the case of an infant with isolated cutaneous involvement at the time of diagnosis of leukaemia. Bone marrow aspiration showed AML M5. The child was treated by LAME 91 protocol, arm "infant under one year of age". Complete remission, both in bone marrow and skin, was obtained after induction course. Then the patient received consolidation course and megatherapy followed by autologous bone marrow transplantation. Skin relapse occurred early. The complete remission no. 2 was not obtained by second line treatment: new LC appeared when PMN count increased more than 10(9)/l. Then, the child was treated with oral VP16 but disease progressed with more and more LC, followed by bone marrow relapse. Child's death occurred about one year after diagnosis.
| ISSN : | 0929-693X |
|---|
| Mesh Heading : | Antineoplastic Combined Chemotherapy Protocols Bone Marrow Transplantation Diagnosis, Differential Fatal Outcome Female Humans Infant Leukemia, Monocytic, Acute Prognosis Recurrence Skin Neoplasms complications drug therapy complications drug therapy |
|---|
| Mesh Heading Relevant : | therapeutic use diagnosis diagnosis |
|---|
Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer.
(2002)
Journal - Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology (United States )
Abstract :
PURPOSE: Infection remains one of the most important complications in cancer therapy. The choice of antibiotics and the method of administration can affect results. Beta-lactam antibiotics can be administered by several short injections per day or by continuous infusion. The latter modality may provide superior pharmacokinetics. PATIENTS AND METHODS: The authors studied the pharmacokinetics of ceftazidime in children treated for malignancy and in febrile aplasia after chemotherapy. They received a continuous infusion of ceftazidime (200 mg/kg/day) after a loading dose (65 mg/kg/day) administered with amikacin (25 mg/kg/day) and vancomycin (50 mg/kg/day).RESULTS Twenty-three pharmacokinetic studies were performed. Mean ceftazidime serum levels were 31.1 +/- 11.9, 31.2 +/- 10, 32.4 +/- 11.6, 33 +/- 11.6, and 30.4 +/- 12.1 mg/L at 25, 27, 30, 36, and 43 hours, respectively. Treatment was tolerated well. There were no toxic or infectious deaths. CONCLUSIONS: Ceftazidime's time-dependent pharmacokinetics shows the advantage of continuous infusion. This study confirmed the feasibility and safety of this administration schedule in the empiric treatment of febrile neutropenic children with cancer.
| ISSN : | 1077-4114 |
|---|
| Mesh Heading : | Adolescent Anti-Bacterial Agents Antineoplastic Agents Ceftazidime Child Child, Preschool Fever Humans Infant Infusions, Intravenous Neoplasms Neutropenia administration & dosage blood pharmacokinetics therapeutic use adverse effects administration & dosage blood etiology chemically induced |
|---|
| Mesh Heading Relevant : | pharmacokinetics therapeutic use drug therapy drug therapy |
|---|
Testicular disease in childhood B-cell non-Hodgkin's lymphoma: the French Society of Pediatric Oncology experience.
(2001)
Journal - Journal of clinical oncology : official journal of the American Society of Clinical Oncology (United States )
Abstract :
PURPOSE: To investigate whether testicular disease in childhood B-cell lymphoma should continue to be considered a sanctuary site, as it is with other lymphoid malignancies such as acute lymphoblastic leukemia. PATIENTS AND METHODS: Seven hundred forty-two children with B-cell non-Hodgkin's lymphoma were included in the LMB protocols of the French Society of Pediatric Oncology from February 1981 to May 1994. Thirty patients (5.3%) had testicular involvement at diagnosis. We describe the clinical presentation and outcome of these 30 patients, who were treated without local radiation therapy. RESULTS: Five patients underwent diagnostic orchidectomy. The median patient age was 8.5 years (range, 2 to 14 years), and their cancers were stage III (18 patients), stage IV (five patients), and B-cell acute lymphoblastic leukemia (seven patients). Five patients had central nervous system involvement. Twenty-eight patients (95%) achieved complete remission. Twenty-six patients are alive without progressive disease (median follow-up, 6.5 years). CONCLUSION: Testicular disease does not seem to confer a poor prognosis, and it is curable with intensive combination chemotherapy alone. Local treatment (surgery or radiation) is avoidable; therefore, gonadal function can be preserved.
| ISSN : | 0732-183X |
|---|
| Mesh Heading : | Adolescent Child Child, Preschool Combined Modality Therapy Humans Lymphoma, B-Cell Male Testicular Neoplasms Treatment Outcome mortality physiopathology |
|---|
| Mesh Heading Relevant : | therapy therapy |
|---|
[Methotrexate-ciprofloxacin interaction: report of two cases of severe intoxication]
(2001)
Journal - Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie (France )
Abstract :
Methotrexate elimination may be delayed by different drugs. Such a delay may produce severe toxic complications. CASE REPORTS: We report two cases of adolescents treated for malignant diseases who presented a delayed methotrexate elimination even though they received ciprofloxacin. The first patient had already received several courses of methotrexate without toxicity before this episode. The second patient tolerated methotrexate when ciprofloxacin was not associated to the treatment. CONCLUSION: High-dose methotrexate-ciprofloxacin association should be avoided.
| ISSN : | 0929-693X |
|---|
| Mesh Heading : | Adolescent Anti-Infective Agents Antimetabolites, Antineoplastic Bone Neoplasms Ciprofloxacin Drug Interactions Female Humans Male Methotrexate Neuroblastoma Osteosarcoma drug therapy pharmacokinetics drug therapy drug therapy |
|---|
| Mesh Heading Relevant : | adverse effects adverse effects pharmacokinetics adverse effects adverse effects pharmacokinetics |
|---|